Physician profile
Pramod Joseph
NPI 1720222102
$5,267.07
in general payments reported to CMS, 2019-2025
29 companies · $972 in 2025
The $972 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $494 · 2021: $746 · 2022: $972 · 2023: $520 · 2024: $899 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,390.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,187.64 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $829.22 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $448.85 | 2023-2025 | Tremfya, Stelara, Simponi |
| Nestle Healthcare Nutrition INC. | $359.60 | 2021-2023 | |
| Gilead Sciences, INC. | $281.95 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $251.60 | 2019-2023 | Entyvio |
| Boston Scientific Corporation | $248.82 | 2019-2025 | General - Hemostasis, General - Polypectomy |
| Pfizer INC. | $227.34 | 2023-2025 | |
| Braintree Laboratories, INC. | $205.54 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $200.13 | 2024-2025 | Voquezna |
| Intuitive Surgical, INC. | $166.17 | 2019-2022 | |
| Madrigal Pharmaceuticals | $150.00 | 2024 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $125.01 | 2023 | Zeposia |
| Celgene Corporation | $110.46 | 2022-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $70.86 | 2020-2023 | Ocaliva |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $51.42 | 2024-2025 | Ibsrela |
| Evoke Pharma, INC. | $44.99 | 2022 | |
| Redhill Biopharma INC. | $40.33 | 2020-2022 | |
| Medtronic, INC. | $34.28 | 2021-2024 | Interstim |
| Genzyme Corporation | $32.03 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $30.63 | 2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $27.25 | 2019-2020 | |
| Conmed Corporation | $23.95 | 2025 | System 2450, Conmed Biliary, Conmed Hemostasis |
| Olympus America INC. | $22.53 | 2025 | Single Use Repositionable Clip, Single Use Ligating Device |
| Ferring Pharmaceuticals INC. | $21.76 | 2021 | |
| Pharmacosmos Therapeutics INC. | $21.54 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $19.50 | 2022 | |
| Concordia Pharmaceuticals INC. | $18.30 | 2019 | |
| Allergan, INC. | $15.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pramod Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.